Bluebird Bio r eports Q2 revenue $16.1M vs .$6.9M last year

“We are seeing clear evidence that our commercial launch is accelerating, with over 20 cell collections completed in sickle cell disease and beta-thalassemia to date in 2024, and more than 40 additional patients already scheduled to initiate the treatment journey for a bluebird gene therapy by the end of this year,” said Andrew Obenshain, chief executive officer, bluebird bio. “We are further encouraged by the commitment to provide patient access across both commercial and government payers, most recently conveyed through multiple positive Medicaid decisions and the growing number of published coverage policies for LYFGENIA, and we expect approximately 85 patient starts across our portfolio this year.”….Reports Q2 revenue $16.1M vs .$6.9M last year… The Company’s cash, cash equivalents and restricted cash balance was approximately $193 M , including restricted cash of approximately $49M , as of June 30.